San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Announces $45 Million Proposed Public Offering
SAN DIEGO, Dec. 10, 2014 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering…
SAN DIEGO, Dec. 11, 2014 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The…
SAN DIEGO, Dec. 11, 2014 (GLOBE NEWSWIRE) — Woman Care Global (WCG) has announced that it will market the Gynocular, through a distribution agreement with Swedish-based manufacturer Gynius. The Gynocular was developed to make a gold standard cervical examination convenient and accessible…
SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier therapy that is…
SAN DIEGO, Dec. 9, 2014 /PRNewswire/ — Sienna Labs, a leader in the field of biophysics with their patented plasmonic nanoparticle technology, today announced they were selected to present at the 2nd Annual Dermatology Summit on January 11th, 2015 in San…
Pathway Genomics Corporation Adds The Honorable Former U.S. Cabinet Member And Member Of Congress, To Strategic Advisory Board
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that former U.S. Representative and Secretary of Agriculture Dan Glickman joined its strategic advisory board. verall risk factors.Were honored to have Secretary Glickman as part of our advisory board, said Jim Plante, Pathway Genomics…
SAN DIEGO, Dec. 11, 2014 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is…
Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella Pertussis
SAN DIEGO, CA–(Marketwired – Dec 10, 2014) – Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue Bordetella Assay for the detection of Bordetella pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to Bordetella pertussis.
Sanford-Burnham plays a key role in the San Diego Alzheimer’s Project
SAN BRUNO, Calif., Dec. 10, 2014 /PRNewswire/ – Cord Blood Registry® (CBR®) announced today that Geoffrey Crouse, the company’s president and chief executive officer, is one of the 13 members of the founding board of The Cord Blood Association (CBA), a new trade and professional association organized for cord blood banking.
The Cord Blood Association will be an international nonprofit organization that promotes the banking and use of umbilical cord blood and related tissues for disease treatment and regenerative therapies. Cord blood is a rich source of stem cells that can be used for restoring health in a variety of chronic diseases.
“CBA brings together experts from public banks, as well as private banks like CBR, to represent the industry both nationally and internationally in matters of policy, legislation, and regulation and to promote the use of newborn stem cells in clinical research for regenerative medicine,” said Crouse. “I’m excited and honored to sit on the board of directors with such a distinguished group of cord blood industry thought leaders.”
The association’s members represent public and private banks as well as individuals within the cord blood community. Four seats are for representatives of public banks, four for private or family banks, and five from the banking community at large. The at-large directors will include a wider set of participants, including research investigators, transplant clinicians, patients, obstetricians, pediatricians, nurses, midwives, vendors, health policy experts and/or regulatory officials.
The founding directors were nominated and invited to serve by an organizing committee that worked throughout the summer on a plan for the new association. The committee based the plan on the consensus of attendees at an open hearing at the International Cord Blood Symposium last June in San Francisco. Polling of the approximately 150 people at the hearing showed a substantial majority (78 percent) favored the creation of an industry-‐wide association. The rest said that they were undecided (18 percent) or opposed (4 percent). The plan for the association was published online in mid-‐August and extensively publicized, along with a request for comments and recommendations from those in and served by the cord blood community.
The plan identifies five initial priorities for the new association:
Quality products and services – through promotion of standards and accreditation
Advocacy – by representing the industry nationally and internationally in matters of health care policy, legislation, regulation and public and private healthcare programs
Market expansion – with readily available consumer access to banking services and cellular therapies
Research and development – through advancement and rapid adoption of novel technologies and therapies
Education – with aware, informed and empowered parents, healthcare providers and general publicIn their first meeting, at a date and location yet to be determined, the founding directors will elect officers, fix term lengths and begin work on the myriad decisions about the new association’s function, programs and activities, including member benefits and recruitment.
The members of the founding board include:
Sue Armitage, BS, Assistant Director, MD Anderson Cord Blood Bank, Houston, TX
David Blackett, Vice President of Marketing and Strategy, PerkinElmer ViaCord, Waltham, MA
Haywood Brown, MD, Chair, Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC
Geoffrey Crouse, MBA, MPH, President & CEO, Cord Blood Registry, San Francisco, CA
Colleen Delaney, MD, MSc, Director, Program in Cord Blood Research and Transplantation, Fred Hutchinson Cancer Research Center, Seattle, WA
Arthur Flatau, PhD, Patient Advocate, Bone Marrow Transplant Survivor, Austin, TX
Kenneth Giacin, MS, MBA, Vice Chairman and Director, StemCyte International, Covina, CA
Prof. Gesine Koegler, PhD, Director, Jose Carreras Cord Blood Bank and GMP Facility, University of Duesseldorf Medical Center, Duesseldorf, DEU
Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank, Durham, NC
Richard L. Lockie, MBA, President & CEO, Insception Biosciences Inc., Toronto, CAD
Aby J. Mathew, PhD, Senior Vice President and Chief Technology Officer, BioLife Solutions, Inc., Bothell, WA
Beth H. Shaz, MD, Chief Medical Officer & Senior Vice President, New York Blood Center, New York, NY
Mahendra Rao, MBBS, PhD, Vice President for Regenerative Medicine, New York Stem Cell Foundation, New York, NYThe tenure for the founding directors will be determined by lottery so that a rotation of board terms can begin. Future directors will be elected to four-‐year terms. Officers for the new association will be chosen from among the board members and announced immediately after their election by the board.
About Cord Blood Registry
Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials, for conditions that have no cure today. For more information, visit cordblood.com.
SOURCE Cord Blood Registry (CBR)